Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

Dublin, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The "Anemia Treatment Market Report by Disease Type, Therapy Class, Route of Administration, Countries and Company Analysis, 2025-2033" report has been added ...

New findings by investigators at the University of Virginia School of Medicine could lead the way to better treatments for anemia, a lack of iron that leaves millions of people feeling weak, unable to ...

EXTON, Pa., July 14, 2020 /PRNewswire/ -- Spherix recently fielded a survey of 152 hematologists/oncologists in the US in order to assess the current and future ...

An oral pyruvate kinase (PK) activator, mitapivat becomes the only approved option for treating anemia in both ...

In the prospective CKD-DOPPS study, only 40% for patients with hemoglobin less than 10 g/dL initiated anemia medication. Only a subset of patients with nondialysis-dependent chronic kidney disease ...

Inflammatory bowel disease (IBD) is commonly associated with iron deficiency anemia (IDA), with a multifactorial pathophysiology. Diagnosis of both IDA and IBD places patients at risk for poor quality ...

Background Up to half of patients with infective endocarditis (IE) require cardiac surgery. Although anaemia is common, its precise prevalence, transfusion practices and impact on outcomes in ...

Anemia, having a lower than normal amount of red blood cells or hemoglobin, is the most common blood disorder in the U.S. Red blood cells’ iron-rich protein called hemoglobin carries oxygen from the ...

The biopharmaceutical company said Tuesday that Aqvesme is now the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.